T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
Hackensack Meridian Health has been using its test on patients suspected of being infected with the virus under the U.S. Food and Drug Administration's emergency use authorization guidance.
Under terms of the pact, T2 Biosystems will adapt the novel coronavirus test to run on its T2Dx instrument, along with the company's T2Bacteria and T2Candida panels. By adding the SARS-CoV-2 test to its T2Dx platform, T2 Biosystems can assess patients suspected of primary or secondary infections associated with the virus. The results will help clinicians quarantine and treat patients and better allocate critical resources, according to the company.
Per the deal, the health network plans to adopt the T2Dx instrument and test panels within its Center for Discovery and Innovation. Hackensack Meridian Health includes 17 hospitals from Bergen to Ocean counties, a behavioral health hospital, and two rehabilitation hospitals. Additionally, the network has more than 500 patient care locations throughout the state, which include ambulatory care centers, surgery centers, home health services, and long-term care and assisted living communities.